ZENAS BIOPHARMA INC (ZBIO) Stock Price, Forecast & Analysis
NASDAQ:ZBIO • US98937L1052
ZBIO Key Statistics, Chart & Performance
The current stock price of ZBIO is 26.35 USD. In the past month the price increased by 26.2%. In the past year, price increased by 275.89%.
ZBIO Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ZBIO. When comparing the yearly performance of all stocks, ZBIO is one of the better performing stocks in the market, outperforming 97.23% of all stocks.
ZBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ZBIO. The financial health of ZBIO is average, but there are quite some concerns on its profitability.
ZBIO Financial Highlights
Over the last trailing twelve months ZBIO reported a non-GAAP Earnings per Share(EPS) of -7.26. The EPS decreased by -296.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -58.97% | ||
| ROE | -96.68% | ||
| Debt/Equity | 0.37 |
ZBIO Forecast & Estimates
14 analysts have analysed ZBIO and the average price target is 41.57 USD. This implies a price increase of 57.74% is expected in the next year compared to the current price of 26.35.
ZBIO Ownership
ZBIO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.98 | 410.174B | ||
| AMGN | AMGEN INC | 17.23 | 209.016B | ||
| GILD | GILEAD SCIENCES INC | 16.7 | 184.799B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.37 | 126.056B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.83 | 82.638B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.7 | 43.982B | ||
| INSM | INSMED INC | N/A | 31.848B | ||
| NTRA | NATERA INC | N/A | 28.947B | ||
| BIIB | BIOGEN INC | 12.61 | 28.152B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.1 | 21.698B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find more ETFs on the USA exchanges | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ZBIO
Company Profile
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company is headquartered in Waltham, Massachusetts and currently employs 130 full-time employees. The company went IPO on 2024-09-13. The firm's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The firm is developing obexelimab as a potential immunology and inflammation (I&I) franchise for patients in several autoimmune diseases. The first three indications it is pursuing include immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). Its other programs include ZB002 (an anti-TNFα monoclonal antibody), ZB004 (a CTLA-4-Ig fusion), and ZB001 and related programs. ZB002 is a recombinant human monoclonal antibody directed at human TNFα.
Company Info
ZENAS BIOPHARMA INC
1000 Winter St, Suite 1200
Waltham MASSACHUSETTS US
Employees: 130
Phone: 18572712954
ZENAS BIOPHARMA INC / ZBIO FAQ
What does ZBIO do?
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company is headquartered in Waltham, Massachusetts and currently employs 130 full-time employees. The company went IPO on 2024-09-13. The firm's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The firm is developing obexelimab as a potential immunology and inflammation (I&I) franchise for patients in several autoimmune diseases. The first three indications it is pursuing include immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). Its other programs include ZB002 (an anti-TNFα monoclonal antibody), ZB004 (a CTLA-4-Ig fusion), and ZB001 and related programs. ZB002 is a recombinant human monoclonal antibody directed at human TNFα.
What is the stock price of ZENAS BIOPHARMA INC today?
The current stock price of ZBIO is 26.35 USD. The price decreased by -0.04% in the last trading session.
Does ZENAS BIOPHARMA INC pay dividends?
ZBIO does not pay a dividend.
What is the ChartMill technical and fundamental rating of ZBIO stock?
ZBIO has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is ZBIO stock listed?
ZBIO stock is listed on the Nasdaq exchange.
When is the next dividend date for ZENAS BIOPHARMA INC (ZBIO)?
The next ex-dividend date for ZENAS BIOPHARMA INC (ZBIO) is December 24, 2019.